{"creationDateTime": "2023-07-31T14:45:52", "datasetJSONVersion": "1.0.0", "fileOID": "UpdatedCDISCPILOT.CDISC SDTM.3.2.TS", "referenceData": {"studyOID": "UpdatedCDISCPILOT.CDISC SDTM.3.2", "metaDataVersionOID": "MDV.UpdatedCDISCPILOT.CDISC SDTM.3.2", "itemGroupData": {"TS": {"records": 48, "name": "TS", "label": "Trial Summary", "items": [{"OID": "ITEMGROUPDATASEQ", "name": "ITEMGROUPDATASEQ", "label": "Record identifier", "type": "integer"}, {"OID": "IT.TS.STUDYID", "name": "STUDYID", "label": "Study Identifier", "type": "string", "length": 12, "keySequence": 1}, {"OID": "IT.TS.DOMAIN", "name": "DOMAIN", "label": "Domain Abbreviation", "type": "string", "length": 2}, {"OID": "IT.TS.TSSEQ", "name": "TSSEQ", "label": "Sequence Number", "type": "integer", "length": 8, "keySequence": 3}, {"OID": "IT.TS.TSPARMCD", "name": "TSPARMCD", "label": "Trial Summary Parameter Short Name", "type": "string", "length": 200, "keySequence": 2}, {"OID": "IT.TS.TSPARM", "name": "TSPARM", "label": "Trial Summary Parameter", "type": "string", "length": 200}, {"OID": "IT.TS.TSVAL", "name": "TSVAL", "label": "Parameter Value", "type": "string", "length": 200}, {"OID": "IT.TS.TSVALNF", "name": "TSVALNF", "label": "Parameter Null Flavor", "type": "string", "length": 4}, {"OID": "IT.TS.TSVALCD", "name": "TSVALCD", "label": "Parameter Value Code", "type": "string", "length": 11}, {"OID": "IT.TS.TSVCDREF", "name": "TSVCDREF", "label": "Name of the Reference Terminology", "type": "string", "length": 8}, {"OID": "IT.TS.TSVCDVER", "name": "TSVCDVER", "label": "Version of the Reference Terminology", "type": "string", "length": 18}], "itemData": [[1, "CDISCPILOT01", "TS", 1, "ADDON", "Added on to Existing Treatments", "N", "", "", "", ""], [2, "CDISCPILOT01", "TS", 1, "AGEMAX", "Planned Maximum Age of Subjects", "", "PINF", "", "", ""], [3, "CDISCPILOT01", "TS", 1, "AGEMIN", "Planned Minimum Age of Subjects", "P50Y", "", "", "", ""], [4, "CDISCPILOT01", "TS", 1, "AGESPAN", "Age Group", "ADULT (18-65)", "", "", "", ""], [5, "CDISCPILOT01", "TS", 2, "AGESPAN", "Age Group", "ELDERLY (> 65)", "", "", "", ""], [6, "CDISCPILOT01", "TS", 1, "TBLIND", "Trial Blinding Schema", "DOUBLE BLIND", "", "", "", ""], [7, "CDISCPILOT01", "TS", 1, "TCNTRL", "Control Type", "PLACEBO", "", "C49648", "CDISC", ""], [8, "CDISCPILOT01", "TS", 1, "TDIGRP", "Diagnosis Group", "Patients with Probable Mild to Moderate Alzheimer\u2019s Disease", "", "", "", ""], [9, "CDISCPILOT01", "TS", 1, "DOSE", "Dose per Administration", "54", "", "", "", ""], [10, "CDISCPILOT01", "TS", 2, "DOSE", "Dose per Administration", "81", "", "", "", ""], [11, "CDISCPILOT01", "TS", 1, "DOSFRQ", "Dosing Frequency", "QD", "", "", "", ""], [12, "CDISCPILOT01", "TS", 1, "DOSU", "Dose Units", "mg", "", "", "", ""], [13, "CDISCPILOT01", "TS", 1, "INDIC", "Trial Indication", "Alzheimer's Disease (Disorder)", "", "26929004", "SNOMED", ""], [14, "CDISCPILOT01", "TS", 1, "TINDTP", "Trial Indication Type", "TREATMENT", "", "", "", ""], [15, "CDISCPILOT01", "TS", 1, "LENGTH", "Trial Length", "P26W", "", "", "", ""], [16, "CDISCPILOT01", "TS", 1, "OBJPRIM", "Trial Primary Objective", "To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])", "", "", "", ""], [17, "CDISCPILOT01", "TS", 2, "OBJPRIM", "Trial Primary Objective", "To document the safety profile of the xanomeline TTS.", "", "", "", ""], [18, "CDISCPILOT01", "TS", 1, "OBJSEC", "Trial Secondary Objective", "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas.", "", "", "", ""], [19, "CDISCPILOT01", "TS", 2, "OBJSEC", "Trial Secondary Objective", "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas.", "", "", "", ""], [20, "CDISCPILOT01", "TS", 3, "OBJSEC", "Trial Secondary Objective", "To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The ADAS-Cog (14) will be used for this assessment.", "", "", "", ""], [21, "CDISCPILOT01", "TS", 4, "OBJSEC", "Trial Secondary Objective", "To assess the treatment response as a function of Apo E genotype.", "", "", "", ""], [22, "CDISCPILOT01", "TS", 1, "TPHASE", "Trial Phase Classification", "PHASE II TRIAL", "", "", "", ""], [23, "CDISCPILOT01", "TS", 1, "PLANSUB", "Planned Number of Subjects", "300", "", "", "", ""], [24, "CDISCPILOT01", "TS", 1, "RANDOM", "Trial is Randomized", "Y", "", "", "", ""], [25, "CDISCPILOT01", "TS", 1, "ROUTE", "Route of Administration", "TRANSDERMAL", "", "", "", ""], [26, "CDISCPILOT01", "TS", 1, "SEXPOP", "Sex of Participants", "BOTH", "", "", "", ""], [27, "CDISCPILOT01", "TS", 1, "SPONSOR", "Clinical Study Sponsor", "CDISCPILOT01", "", "", "", ""], [28, "CDISCPILOT01", "TS", 1, "TITLE", "Trial Title", "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer\u2019s Disease.", "", "", "", ""], [29, "CDISCPILOT01", "TS", 1, "TRT", "Investigational Therapy or Treatment", "Xanomeline", "", "9ORI6L73CJ", "UNII", ""], [30, "CDISCPILOT01", "TS", 1, "TTYPE", "Trial Type", "SAFETY", "", "", "", ""], [31, "CDISCPILOT01", "TS", 2, "TTYPE", "Trial Type", "EFFICACY", "", "", "", ""], [32, "CDISCPILOT01", "TS", 4, "TTYPE", "Trial Type", "PHARMACOKINETIC", "", "", "", ""], [33, "CDISCPILOT01", "TS", 1, "STOPRULE", "Study Stop Rules", "Last patient completed last visit or sponsor decided to discontinue study", "", "", "", ""], [34, "CDISCPILOT01", "TS", 1, "REGID", "Registry Identifier", "NCT00987090", "", "NCT00987090", "", "clinicaltrials.gov"], [35, "CDISCPILOT01", "TS", 1, "OUTMSPRI", "Primary Outcome Measure", "Evaluate the efficacy and safety of transdermal xanomeline, 50cm2 and 75cm2, and placebo in subjects with mild to moderate Alzheimer's disease.", "", "", "", ""], [36, "CDISCPILOT01", "TS", 1, "FCNTRY", "Planned Country of Investigational Sites", "USA", "", "USA", "ISO 3166", ""], [37, "CDISCPILOT01", "TS", 1, "ADAPT", "Adaptive Design", "N", "", "C49487", "CDISC", ""], [38, "CDISCPILOT01", "TS", 1, "DCUTDTC", "Data Cutoff Date", "2015-03-31", "", "", "ISO 8601", ""], [39, "CDISCPILOT01", "TS", 1, "DCUTDESC", "Data Cutoff Description", "Interim Analysis Data Cutoff Date", "", "", "", ""], [40, "CDISCPILOT01", "TS", 1, "NARMS", "Planned Number of Arms", "3", "", "", "", ""], [41, "CDISCPILOT01", "TS", 1, "STYPE", "Study Type", "INTERVENTIONAL", "", "C98388", "CDISC", ""], [42, "CDISCPILOT01", "TS", 1, "SSTDTC", "Study Start Date", "2012-07-06", "", "", "ISO 8601", ""], [43, "CDISCPILOT01", "TS", 1, "SENDTC", "Study End Date", "2015-03-05", "", "", "ISO 8601", ""], [44, "CDISCPILOT01", "TS", 1, "ACTSUB", "Actual Number of Subjects", "254", "", "", "", ""], [45, "CDISCPILOT01", "TS", 1, "HLTSUBJI", "Healthy Subject Indicator", "N", "", "C49487", "CDISC", ""], [46, "CDISCPILOT01", "TS", 1, "INTMODEL", "Intervention Model", "PARALLEL", "", "C82639", "CDISC", ""], [47, "CDISCPILOT01", "TS", 1, "INTTYPE", "Intervention Type", "DRUG", "", "C1909", "CDISC", ""], [48, "CDISCPILOT01", "TS", 1, "PCLAS", "Pharmacologic Class", "Acetylcholine Release Inhibitor", "", "N0000175771", "NDF-RT", ""]]}}}}